This trial is evaluating whether 64Cu-FBP8 will improve 3 primary outcomes and 3 secondary outcomes in patients with Pulmonary Embolism. Measurement will happen over the course of 4 hours.
This trial requires 80 total participants across 1 different treatment group
This trial involves a single treatment. 64Cu-FBP8 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Venous thromboembolic events are a common and serious problem among ambulatory patients, and these events occur most frequently in immobilized and hospitalized patients. A multifactorial investigation of venous thromboembolism should be initiated in patients with suspected venous thromboembolism." - Anonymous Online Contributor
"Signs and symptoms of VTE may include swollen legs, pain and swelling of the legs, fever, and changes to the way one walks. Symptoms last for less than one day and include shortness of breath, chills, and nausea or vomiting.\n" - Anonymous Online Contributor
"While VTE may have a number of risks including an increased risk of bleeding and serious complications of pregnancy, it is still much less costly and risky than other forms of cancer, such as brain cancer and leukemia." - Anonymous Online Contributor
"A number of medical, surgical, and invasive procedures are used to treat patients with venous thromboembolism. A common technique used to treat deep venous thrombosis (DVT) of the legs is compression therapy with compressive stockings. Other common treatments include intravenous (IV) unfractionated heparin, warfarin, and direct Xa inhibitors. An important technique to make the diagnosis of venous thromboembolism is duplex scanning, a test where a venous blood sample is tested for deep venous thrombosis." - Anonymous Online Contributor
"In the past, thromboprophylaxis was often used for the reduction of venous clot propagation and thromboembolism, but this practice was gradually phased out and the clinical application of this standard prophylactic strategy has almost stopped in the past decade. For the last two decades, the treatment of venous thromboembolic disease (VTE) has been mainly with low molecular weight heparin (LMWHs) or mechanical treatment rather than anticoagulants, which require long-term oral anticoagulation or the use of compression garments. Evidence suggests that the use of LMWHs would be efficacious, with fewer discontinuations compared to a standard anticoagulation regimen." - Anonymous Online Contributor
"About 200,000 people suffer a fatal embolism each year in the USA. VTE is a major cause of mortality in patients with hematological malignancies. VTE occurs independently of hematological malignancy and also is strongly associated with use of oral anticoagulation in at risk patients." - Anonymous Online Contributor
"We have shown the efficacy of 64Cu-fbp8 for the treatment of metastatic and advanced carcinomas resulting from [residual or reflux tumors (RT) or recurrent tumours (RT)], and [primary inoperable or advanced RT]. This new radiopharmacy offers a non-invasive solution to the problem of local disease recurrences after a previously successful therapy. The authors have also shown that [FBPC2 is more effective than the previous (b) standard (B, bis-choline-DTPA] in tumour-targeting, enabling a larger drug spread within the tumor." - Anonymous Online Contributor
"This article presents a case of a venous thromboembolism in a patient with a positive family history of venous thromboembolism but no thrombophilia. The 64Cu-fbp8 result demonstrated no activity, thereby eliminating thrombophilia as a possible cause. Although not necessarily clinically significant, this is the first such case reported in the literature." - Anonymous Online Contributor
"[Patients with advanced hepatocellular carcinoma are most likely to benefit from this regimen, while patients with advanced nasopharyngeal carcinoma are likely to benefit the most from an adjuvant regimen (that is, one containing 64Cu-fbp8). In addition, the incidence of venous thrombotic events is higher in patients receiving any other treatment (63.6%) than in patients at high risk for them only undergoing chemo-radio-therapy (37.5%). Thus, 64Cu-fbp8 is typically used in combination with other therapies, such as chemotherapy and/or radio-therapy]] (www.withpower.com/drug-combinations)." - Anonymous Online Contributor
"The increased incidence of pulmonary embolisms in siblings of patients with VTE is suggestive of a genetic basis but does not allow a definite and complete identification of genetic factors involved. The mechanisms involved will require further research." - Anonymous Online Contributor
"FOB (64cu-fbp) is a highly efficient radiopharmaceutical used for positron emission tomography imaging of skeletal and visceral tumors. FOB is associated with a wide spectrum of nonspecific side effects including nausea, fatigue, anorexia, constipation, and dizziness. Further studies are needed to assess the risk factors and mechanisms of these common side effects to improve patient management and minimize their frequency." - Anonymous Online Contributor
"In a recent study, findings shows that, on a single occasion, 64Cu-fbp8 has a transient effect on the development of PE. We conclude that a large clinical trial of 64Cu-fbp8 is justified and discuss possible future targets for future clinical trials." - Anonymous Online Contributor